Atrion (ATRI) Reaches New 52-Week High at $796.00

Atrion Co. (NASDAQ:ATRI) shares hit a new 52-week high on Thursday . The company traded as high as $796.00 and last traded at $792.57, with a volume of 76 shares. The stock had previously closed at $785.70.

Separately, BidaskClub raised Atrion from a “hold” rating to a “buy” rating in a research note on Friday, August 17th.

The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of 41.13 and a beta of 0.57.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings results on Friday, November 9th. The medical instruments supplier reported $4.96 earnings per share for the quarter. The company had revenue of $39.27 million for the quarter. Atrion had a return on equity of 18.01% and a net margin of 23.19%.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 17th. Investors of record on Monday, December 3rd will be given a $1.35 dividend. This represents a $5.40 annualized dividend and a dividend yield of 0.69%. The ex-dividend date is Friday, November 30th.

In related news, CFO Jeffery Strickland sold 2,000 shares of the stock in a transaction on Wednesday, November 28th. The stock was sold at an average price of $768.07, for a total value of $1,536,140.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 22.46% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Bahl & Gaynor Inc. grew its stake in Atrion by 3.3% in the third quarter. Bahl & Gaynor Inc. now owns 2,407 shares of the medical instruments supplier’s stock worth $1,673,000 after purchasing an additional 77 shares in the last quarter. Strs Ohio grew its stake in Atrion by 7.7% in the second quarter. Strs Ohio now owns 1,400 shares of the medical instruments supplier’s stock worth $839,000 after purchasing an additional 100 shares in the last quarter. Schroder Investment Management Group grew its stake in Atrion by 11.7% in the second quarter. Schroder Investment Management Group now owns 1,033 shares of the medical instruments supplier’s stock worth $619,000 after purchasing an additional 108 shares in the last quarter. Aperio Group LLC grew its stake in Atrion by 8.8% in the second quarter. Aperio Group LLC now owns 1,378 shares of the medical instruments supplier’s stock worth $826,000 after purchasing an additional 112 shares in the last quarter. Finally, Teachers Advisors LLC grew its stake in Atrion by 5.0% in the third quarter. Teachers Advisors LLC now owns 3,007 shares of the medical instruments supplier’s stock worth $2,089,000 after purchasing an additional 143 shares in the last quarter. Institutional investors own 63.56% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Atrion (ATRI) Reaches New 52-Week High at $796.00” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2018/12/08/atrion-atri-reaches-new-52-week-high-at-796-00.html.

About Atrion (NASDAQ:ATRI)

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

See Also: Cash Flow

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply